Relationship between serum sialic acids, sialic acid-rich inflammation-sensitive proteins and cell damage in patients with acute myocardial infarction

• Published in: Clinical chemistry and laboratory medicine Vol. 44; no. 2; pp. 199 - 206
• Main Authors: Süer Gökmen, Selma, Kazezoğlu, Cemal, Sunar, Bendigar, Özçelik, Fatih, Güngör, Özgül, Yorulmaz, Faruk, Gülen, Şendoğan
• Format: Journal Article
• Language: English
• Published: Berlin De Gruyter 01.02.2006; New York, NY Walter de Gruyter
• Subjects: alpha 1-Antitrypsin - analysis; alpha-Macroglobulins - analysis; Biological and medical sciences; Biomarkers - blood; cell damage; Ceruloplasmin - analysis; Female; General aspects; Humans; Inflammation - blood; Investigative techniques, diagnostic techniques (general aspects); lipid-bound sialic acid; Male; Medical sciences; Middle Aged; myocardial infarction; Myocardial Infarction - blood; Myocardial Infarction - immunology; N-Acetylneuraminic Acid - blood; sialic acid-rich inflammation-sensitive proteins; total sialic acid; Human; Myocardial infarction; sialic acid-rich inflammation-sensitive proteins; Sialic acid; Acute; total sialic acid; Cardiovascular disease; Inflammation; Myocardial disease; Protein; Medicine; cell damage; Heart disease; Clinical biology; Serum; Lesion; lipid-bound sialic acid
• ISSN: 1434-6621; 1437-4331
• DOI: 10.1515/CCLM.2006.037

The role of sialic acid (SA) in the pathogenesis of atherosclerosis and as a predictor of cardiovascular events has attracted much attention in recent years. However, most studies investigating the role of total and lipid-bound sialic acids (TSA and LSA) in the pathogenesis of atherosclerosis lack information on the reason for the elevated SA concentrations in coronary heart disease and myocardial infarction. Since the inflammation-sensitive proteins are glycoproteins with SA residues, an increase in their levels due to some type of acute-phase reaction or inflammation could be responsible for the elevated TSA levels in acute myocardial infarction (AMI). Elevated serum SA levels might also be due to either shedding or secretion of free SA from the cell or cell membrane surface if neuraminidase levels are increased, or to the release of cellular SA-containing glycolipids and/or glycoproteins into plasma from myocardial cells after AMI. The aim of the present study was to investigate both the possible role of SA-rich inflammation-sensitive proteins and the cell damage due to elevated serum TSA levels in AMI. A possible role of serum LSA as an indicator of the shedding or secretion of SA from the cell or cell membrane surface in AMI was also evaluated. The study included 38 subjects with AMI and 32 healthy volunteers. Serum TSA and LSA were determined using the methods of Warren and Katopodis, respectively. The concentrations of serum SA-rich inflammation-sensitive proteins, namely α -antitrypsin, α -macroglobulin and ceruloplasmin were determined immunoturbidimetrically. Our data showed that: a) mean levels of serum TSA and LSA and SA-rich inflammation-sensitive proteins in patients with AMI were significantly increased; and b) there was a significant positive correlation between TSA and LSA and α -antitrypsin in patients with AMI. Since the transfer of free SA to lipoproteins is required for an increase in serum LSA levels, and free SA for this transfer can be provided by the secretion of SA from the cell, it is obvious that the shedding or secretion of SA from the cell membrane surface or release of cellular SA from cells into the bloodstream due to cell damage after AMI also occur after AMI. As a result, we can report that either the shedding or secretion of SA from the cell or cell membrane surface and the increased output of SA-rich inflammation-sensitive proteins may together be responsible for the elevated TSA levels in AMI.